The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-κB activation
Open accessAbstract
Tissue damage is usually followed by healing, as both differentiated and stem cells migrate to replace dead or damaged cells. Mesoangioblasts (vessel-associated stem cells that can repair muscles) and fibroblasts migrate toward soluble factors released by damaged tissue. Two such factors are high mobility group box 1 (HMGB1), a nuclear protein that is released by cells undergoing unscheduled death (necrosis) but not by apoptotic cells, and stromal derived factor (SDF)–1/CXCL12. We find that HMGB1 activates the canonical nuclear factor κB (NF-κB) pathway via extracellular signal-regulated kinase phosphorylation. NF-κB signaling is necessary for chemotaxis toward HMGB1 and SDF-1/CXCL12, but not toward growth factor platelet-derived growth factor, formyl-met-leu-phe (a peptide that mimics bacterial invasion), or the archetypal NF-κB–activating signal tumor necrosis factor α. In dystrophic mice, mesoangioblasts injected into the general circulation ingress inefficiently into muscles if their NF-κB signaling pathway is disabled. These findings suggest that NF-κB signaling controls tissue regeneration in addition to early events in inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
Self-citationDAMPs, PAMPs and alarmins: all we need to know about danger
Bianchi, M. E. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306164 · Cited by 2,794
Self-citationThe two NF-κB activation pathways and their role in innate and adaptive immunity
Bonizzi, G., & Karin, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.008 · Cited by 2,535
Understanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297 · cited 2×
“RAGE has been reported to activate MAPKs; both RAGE and Toll-like receptors activate NF-κB (Bonizzi and Karin, 2004; Bierhaus et al., 2005).”
BackgroundThe Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25752 · Cited by 1,151
Minasi, M. G., Riminucci, M., De Angelis, L., Borello, U., Berarducci, B., Innocenzi, A., Caprioli, A., Sirabella, D., Baiocchi, M., De Maria, R., et al. (2002) · Development · doi:10.1242/dev.129.11.2773 · Cited by 514
Self-citation
Cited by
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
Neuroinflammation: friend and foe for ischemic stroke
Jayaraj, R. L., Azimullah, S., Beiram, R., Jalal, F. Y., & Rosenberg, G. A. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1516-2 · Cited by 1,428
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
HMGB1: Endogenous Danger Signaling
Klune, J. R., Dhupar, R., Cardinal, J., Billiar, T. R., & Tsung, A. (2008) · Molecular Medicine · doi:10.2119/2008-00034.klune · Cited by 762
Cartilage homeostasis in health and rheumatic diseases
Goldring, M. B., & Marcu, K. B. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2592 · Cited by 762
Self-citationMutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release
Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D. J., Cattaneo, A., De Marchis, F., Liu, J., Antonelli, A., Preti, A., Raeli, L., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120189 · Cited by 720
“Fibroblasts, respond to lower concentrations of HMGB1 compared with leukocytes (Palumbo et al., 2007) and support their own migration by secreting CXCL12 both basally and in response to HMGB1 activation of the receptor for advanced glycation end products (RAGE; Schiraldi et al., 2012).”
BackgroundSelf-citationHMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease
Harris, H. E., Andersson, U., & Pisetsky, D. S. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.222 · Cited by 689
Raucci, A., Cugusi, S., Antonelli, A., Barabino, S. M., Monti, L., Bierhaus, A., Reiss, K., Saftig, P., & Bianchi, M. E. (2008) · The FASEB Journal · doi:10.1096/fj.08-109033 · Cited by 555
Self-citationHigh-Mobility Group Box 1, Oxidative Stress, and Disease
Tang, D., Kang, R., Zeh, H. J., & Lotze, M. T. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3356 · Cited by 468
p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes
Davalos, A. R., Kawahara, M., Malhotra, G. K., Schaum, N., Huang, J., Ved, U., Beausejour, C. M., Coppe, J.-P., Rodier, F., & Campisi, J. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201206006 · Cited by 439
“9 F), as demonstrated for mouse cells (Palumbo et al., 2007).”
Sasportas, L. S., Kasmieh, R., Wakimoto, H., Hingtgen, S., van de Water, J. A. J. M., Mohapatra, G., Figueiredo, J. L., Martuza, R. L., Weissleder, R., & Shah, K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806647106 · Cited by 455
Ceulemans, A.-G., Zgavc, T., Kooijman, R., Hachimi-Idrissi, S., Sarre, S., & Michotte, Y. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-74 · Cited by 351
“Binding of HMGB1 to RAGE also stimulates chemotaxis [80-82].”
BackgroundAn overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
Musumeci, D., Roviello, G. N., & Montesarchio, D. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.001 · Cited by 334
Clinical applications of mesenchymal stem cells
Kim, N., & Cho, S.-G. (2013) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2013.28.4.387 · Cited by 314
Endometriosis, a disease of the macrophage
Capobianco, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00009 · Cited by 304
Prospects for Stem Cell-Based Therapy
Daley, G. Q., & Scadden, D. T. (2008) · Cell · doi:10.1016/j.cell.2008.02.009 · Cited by 302
Stem and progenitor cell-mediated tumor selective gene therapy
Aboody, K. S., Najbauer, J., & Danks, M. K. (2008) · Gene Therapy · doi:10.1038/gt.2008.41 · Cited by 270
Lolmede, K., Campana, L., Vezzoli, M., Bosurgi, L., Tonlorenzi, R., Clementi, E., Bianchi, M. E., Cossu, G., Manfredi, A. A., Brunelli, S., et al. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0908579 · Cited by 216
Self-citationHigh‐mobility group box‐1 in sterile inflammation
Tsung, A., Tohme, S., & Billiar, T. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12276 · Cited by 187
CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns
Liu, Y., Chen, G.-Y., & Zheng, P. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.09.006 · Cited by 147
Bianchi, M. E., & Manfredi, A. A. (2009) · Science · doi:10.1126/science.1172794 · Cited by 117
Self-citationHMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17‐cell expansion
Su, Z., Sun, C., Zhou, C., Liu, Y., Zhu, H., Sandoghchian, S., Zheng, D., Peng, T., Zhang, Y., Jiao, Z., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201141879 · Cited by 81
Su, Z., Yin, J., Wang, T., Sun, Y., Ni, P., Ma, R., Zhu, H., Zheng, D., Shen, H., Xu, W., et al. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12324 · Cited by 33
Sialoside-based pattern recognitions discriminating infections from tissue injuries
Liu, Y., Chen, G.-Y., & Zheng, P. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.10.004 · Cited by 28
Metadata
- Authors
- Palumbo, R., Galvez, B. G., Pusterla, T., De Marchis, F., Cossu, G., Marcu, K. B., & Bianchi, M. E.
- Venue
- The Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2007-10-08
- Volume
- 179
- Issue
- 1
- Pages
- 33-40
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- OpenAlex
- W2095609344
- Cited by
- 250
- References
- 6
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.